WR 279,396 for the Treatment of Cutaneous Leishmaniasis

NCT01988909 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Cutaneous Leishmaniasis

Interventions

DRUG: WR 279,396

Sponsor

Assistance Publique - Hôpitaux de Paris

Collaborators

[object Object]